GMAB · NASDAQ · STOCK
Genmab A/S (GMAB) Stock Analysis
$37.99
52W $23.62 – $40.17
59/100
$22.45B
28.6
0.65
Is GMAB Bullish or Bearish?
Bullish.
Innellis AI committee rates Genmab A/S (GMAB) Buy with a composite score of 59/100
, based on 5 analysts with 60% agreement.
Last updated October 14, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +15.92 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -4.08 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Technical Analyst sees a compelling case — price structure making higher highs and higher lows. Portfolio Manager remains cautious — 2 existing position pair(s) are highly correlated already. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- P/E of 28.2 is moderate-to-rich — Value
- EPS declining -36.4% YoY despite any revenue growth — Growth
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 14, 2026
Overall Committee Score
59/100
Agreement
60%
Analysts
5
Conviction
Moderate
Sector Rank
Top 38%
of 192 Healthcare peers
Value Analyst
neutral
48
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− P/E of 28.2 is moderate-to-rich
Growth Analyst
neutral
57
/ 100 · High confidence
Moderate growth -- present but not remarkable
+ Quarter-over-quarter growth rate is ACCELERATING, not just positive
− EPS declining -36.4% YoY despite any revenue growth
Technical Analyst
bullish
69
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
neutral
58
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager
bearish
35
/ 100 · Low confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− 2 existing position pair(s) are highly correlated already
Investment Thesis Evolution
Committee score weakened from 62.5 to 59.1.
- New bearish signals: 1 appeared.
- Bullish support removed: 1 signal(s) disappeared.
- Bearish pressure eased: 3 signal(s) disappeared.
Analyst-level changes:
- Macro Analyst: score 80->65 (-15).
- Portfolio Manager: score 30->35 (+5).
- Value Analyst: +1 bearish signal(s).
Comparing 2026-10-13 to 2026-10-14 (1 day apart).
Technical Analysis
RSI (14)
56.4
Neutral
MACD Histogram
-0.008
Bearish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Hh Hl
Bollinger %B
0.72
Inside Bands
Price vs Moving Averages
EMA 9
$36.62
Above
EMA 21
$35.80
Above
EMA 50
$33.99
Above
EMA 200
$30.18
Above
Fundamental Analysis
Valuation
70
Growth
70
Profitability
62
Financial Health
90
Cash Flow
70
Valuation
P/E Ratio
28.6×
P/B Ratio
3.77×
PEG Ratio
-0.33
Dividend Yield
0.00%
52W High
$40.17
52W Low
$23.62
Quality & Growth
ROE
1652.1%
ROA
750.4%
Gross Margin
3991.8%
Operating Margin
1381.2%
Revenue Growth YoY
—
Debt / Equity
0.89
AI Fundamental Assessment
P/E ratio of 28.6 (moderate relative to a 15-40x range); Price-to-book of 3.8x; PEG ratio of -0.3 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 16.5%; Return on assets of 7.5%; Net margin of 8.2%; Gross margin of 39.9%; Current ratio of 2.46 (healthy short-term liquidity); Debt-to-equity of 0.89; Free cash flow per share is positive (1.42); Most recent quarter beat estimates by 36.6%; EPS growth accelerating (-61.0% -> +491.6% QoQ); Analyst estimates rising over recent quarters
Get the Full GMAB Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →